Emergent BioSolutions Signs $50M Agreement with SAB Biotherapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy EBS?
Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical development for autoimmune type 1 diabetes. The executed agreement is valued at approximately $50M, of which $36M is contingent on future regulatory approval and downstream milestones. Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will include process development and scale-up, technology and analytical method transfer, manufacturing for SAB-142's ongoing clinical program and commercial manufacturing services upon regulatory approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.230
Low
15.00
Averages
15.00
High
15.00
Current: 8.230
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emergent BioSolutions Enters $50M Agreement with SAB Biotherapeutics
- Contract Value: Emergent BioSolutions has entered a multi-year agreement valued at approximately $50 million with SAB Biotherapeutics, with $36 million contingent on regulatory approval and milestone achievements, indicating strong confidence in the drug development process.
- Support Services: The agreement entails Emergent providing process development, scale-up, technology transfer, and manufacturing services to support the clinical program of SAB-142, enhancing its competitive edge in the market.
- Commercial Manufacturing Potential: Should SAB-142 receive approval, Emergent will also handle its commercial manufacturing, which not only opens a potential revenue stream for the company but also further solidifies its position in the biopharmaceutical sector.
- Market Reaction: Following the announcement, Emergent's stock rose 2.19% in premarket trading to $8.41, reflecting positive investor sentiment towards the collaboration.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million, with $36 million contingent on future regulatory approvals and milestones, indicating strong confidence in the project's success.
- Enhanced Manufacturing Capabilities: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices at its Winnipeg facility, ensuring smooth progress for SAB-142's clinical program and future commercial production.
- Technology Transfer and Scale-Up: The agreement includes services for process development and analytical method transfer, which will accelerate the clinical progression of SAB-142, potentially offering new treatment options for diabetes patients and holding significant market potential.
- Strategic Partnership: This collaboration not only showcases Emergent's expertise in the biopharmaceutical sector but also reflects SAB BIO's commitment to developing innovative therapies for autoimmune diabetes, with their partnership poised to advance the commercialization of new therapies.
See More
Emergent BioSolutions Enters $34.5M Vaccine Agreement with Substipharm
- Vaccine Production Agreement: Emergent BioSolutions has entered into a $34.5 million agreement with Substipharm Biologics, focusing on drug substance production for the IMOJEV Japanese Encephalitis vaccine, marking a strategic expansion in the vaccine sector.
- Exclusive Distribution Rights: Under the agreement, Emergent will serve as the exclusive distributor to the U.S. government pending FDA approval, ensuring its critical role and market access in public health.
- Production Capacity Increase: This agreement will drive Emergent to scale up production at its Canton, Massachusetts facility and plans to hire additional staff to meet the growing vaccine demand.
- Regulatory Support: The collaboration will support Emergent's regulatory submission efforts for U.S. vaccine approval, further solidifying its position in the biopharmaceutical industry and driving future growth.
See More
Emergent Partners with BC Health Authority to Expand NARCAN® Program
- Partnership Expansion: Emergent BioSolutions has partnered with the B.C. Provincial Health Services Authority to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program, following an $18 million CAD investment by the B.C. government aimed at enhancing community access to naloxone and addressing the opioid crisis.
- Delivery Milestones: Since 2016, Emergent has delivered over 100 million doses of NARCAN® Nasal Spray across Canada and the U.S., showcasing the company's robust capability in responding to public health threats and solidifying its leadership in life-saving products.
- Community Impact: The expansion will make NARCAN® Nasal Spray available in various communities, pharmacies, and public institutions across B.C., significantly enhancing public response capabilities to opioid overdoses and potentially reducing related mortality rates.
- Strategic Collaboration: Emergent's close partnership with B.C. public health authorities underscores the company's commitment to addressing public health crises, with plans to continue supporting community health and safety through product innovation and strategic initiatives.
See More
Emergent BioSolutions Secures $54M Contract for Smallpox Preparedness
- Contract Award: Emergent BioSolutions announced it has secured a contract valued at approximately $54 million to deliver CNJ-016® to the U.S. Department of Health and Human Services' ASPR, enhancing smallpox preparedness and underscoring the company's critical role in biodefense.
- Incremental Orders: The company has also secured new incremental orders worth $6.6 million with an international government partner for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), which will support the partner's smallpox biodefense strategy, further solidifying Emergent's market position.
- Canadian Agreements: Emergent recently executed multi-year agreements with the Government of Canada valued at up to C$140 million to bolster the country's biologic threat preparedness and response infrastructure, with over C$35 million in orders expected in 2026, showcasing the company's expansion potential in international markets.
- Financial Outlook: Despite facing challenges with weak 2026 revenue guidance, Emergent BioSolutions has set a revenue target of $720 million to $760 million for 2026, indicating that the company is advancing its transformation plan to achieve long-term growth.
See More
Emergent BioSolutions Secures $54 Million Contract for Smallpox Preparedness
- Significant Contract Value: Emergent BioSolutions has secured a contract worth approximately $54 million to deliver CNJ-016® to the ASPR, enhancing U.S. capabilities in treating complications from smallpox vaccination, thereby bolstering national public health security.
- Incremental International Orders: The company has also received new orders valued at $6.6 million from an international government partner for ACAM2000® vaccine, which not only supports the partner's biodefense strategy but also highlights Emergent's importance in global threat preparedness.
- Long-Term Partnerships: Emergent's multi-year agreements with the Government of Canada, valued up to CAD 140 million, with over CAD 35 million in orders expected in 2026, demonstrate the company's strong position and market demand in the biological threat preparedness sector.
- Product Safety Information: Both CNJ-016® and ACAM2000® have FDA-approved indications and important safety information, ensuring effective management of health risks for patients during use, further solidifying Emergent's leadership in the biodefense product market.
See More
Emergent BioSolutions Enters $50M Agreement with SAB Biotherapeutics
- Contract Value: Emergent BioSolutions has entered a multi-year agreement valued at approximately $50 million with SAB Biotherapeutics, with $36 million contingent on regulatory approval and milestone achievements, indicating strong confidence in the drug development process.
- Support Services: The agreement entails Emergent providing process development, scale-up, technology transfer, and manufacturing services to support the clinical program of SAB-142, enhancing its competitive edge in the market.
- Commercial Manufacturing Potential: Should SAB-142 receive approval, Emergent will also handle its commercial manufacturing, which not only opens a potential revenue stream for the company but also further solidifies its position in the biopharmaceutical sector.
- Market Reaction: Following the announcement, Emergent's stock rose 2.19% in premarket trading to $8.41, reflecting positive investor sentiment towards the collaboration.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million, with $36 million contingent on future regulatory approvals and milestones, indicating strong confidence in the project's success.
- Enhanced Manufacturing Capabilities: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices at its Winnipeg facility, ensuring smooth progress for SAB-142's clinical program and future commercial production.
- Technology Transfer and Scale-Up: The agreement includes services for process development and analytical method transfer, which will accelerate the clinical progression of SAB-142, potentially offering new treatment options for diabetes patients and holding significant market potential.
- Strategic Partnership: This collaboration not only showcases Emergent's expertise in the biopharmaceutical sector but also reflects SAB BIO's commitment to developing innovative therapies for autoimmune diabetes, with their partnership poised to advance the commercialization of new therapies.
See More
Emergent BioSolutions Enters $34.5M Vaccine Agreement with Substipharm
- Vaccine Production Agreement: Emergent BioSolutions has entered into a $34.5 million agreement with Substipharm Biologics, focusing on drug substance production for the IMOJEV Japanese Encephalitis vaccine, marking a strategic expansion in the vaccine sector.
- Exclusive Distribution Rights: Under the agreement, Emergent will serve as the exclusive distributor to the U.S. government pending FDA approval, ensuring its critical role and market access in public health.
- Production Capacity Increase: This agreement will drive Emergent to scale up production at its Canton, Massachusetts facility and plans to hire additional staff to meet the growing vaccine demand.
- Regulatory Support: The collaboration will support Emergent's regulatory submission efforts for U.S. vaccine approval, further solidifying its position in the biopharmaceutical industry and driving future growth.
See More
Emergent Partners with BC Health Authority to Expand NARCAN® Program
- Partnership Expansion: Emergent BioSolutions has partnered with the B.C. Provincial Health Services Authority to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program, following an $18 million CAD investment by the B.C. government aimed at enhancing community access to naloxone and addressing the opioid crisis.
- Delivery Milestones: Since 2016, Emergent has delivered over 100 million doses of NARCAN® Nasal Spray across Canada and the U.S., showcasing the company's robust capability in responding to public health threats and solidifying its leadership in life-saving products.
- Community Impact: The expansion will make NARCAN® Nasal Spray available in various communities, pharmacies, and public institutions across B.C., significantly enhancing public response capabilities to opioid overdoses and potentially reducing related mortality rates.
- Strategic Collaboration: Emergent's close partnership with B.C. public health authorities underscores the company's commitment to addressing public health crises, with plans to continue supporting community health and safety through product innovation and strategic initiatives.
See More
Emergent BioSolutions Secures $54M Contract for Smallpox Preparedness
- Contract Award: Emergent BioSolutions announced it has secured a contract valued at approximately $54 million to deliver CNJ-016® to the U.S. Department of Health and Human Services' ASPR, enhancing smallpox preparedness and underscoring the company's critical role in biodefense.
- Incremental Orders: The company has also secured new incremental orders worth $6.6 million with an international government partner for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), which will support the partner's smallpox biodefense strategy, further solidifying Emergent's market position.
- Canadian Agreements: Emergent recently executed multi-year agreements with the Government of Canada valued at up to C$140 million to bolster the country's biologic threat preparedness and response infrastructure, with over C$35 million in orders expected in 2026, showcasing the company's expansion potential in international markets.
- Financial Outlook: Despite facing challenges with weak 2026 revenue guidance, Emergent BioSolutions has set a revenue target of $720 million to $760 million for 2026, indicating that the company is advancing its transformation plan to achieve long-term growth.
See More
Emergent BioSolutions Secures $54 Million Contract for Smallpox Preparedness
- Significant Contract Value: Emergent BioSolutions has secured a contract worth approximately $54 million to deliver CNJ-016® to the ASPR, enhancing U.S. capabilities in treating complications from smallpox vaccination, thereby bolstering national public health security.
- Incremental International Orders: The company has also received new orders valued at $6.6 million from an international government partner for ACAM2000® vaccine, which not only supports the partner's biodefense strategy but also highlights Emergent's importance in global threat preparedness.
- Long-Term Partnerships: Emergent's multi-year agreements with the Government of Canada, valued up to CAD 140 million, with over CAD 35 million in orders expected in 2026, demonstrate the company's strong position and market demand in the biological threat preparedness sector.
- Product Safety Information: Both CNJ-016® and ACAM2000® have FDA-approved indications and important safety information, ensuring effective management of health risks for patients during use, further solidifying Emergent's leadership in the biodefense product market.
See More
